The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.
 
Ariel Ann Nelson
No Relationships to Disclose
 
Robert Cronk
No Relationships to Disclose
 
Aniko Szabo
No Relationships to Disclose
 
Emily Lemke
No Relationships to Disclose
 
Thomas A. Giever
No Relationships to Disclose
 
John D. Burfeind
Stock and Other Ownership Interests - MedicaLogic
Patents, Royalties, Other Intellectual Property - I have a one third interest in IP related to clinical trial management software developed by Medicalogic.io.
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Sanofi
Speakers' Bureau - Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Matthew John Riese
No Relationships to Disclose
 
Kathryn A. Bylow
No Relationships to Disclose
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Ali Raza Khaki
Stock and Other Ownership Interests - Pfizer; Procter & Gamble; Walgreens Boots Alliance
 
Behtash Nezami
No Relationships to Disclose
 
Gregory MacLennan
No Relationships to Disclose
 
Mary Ann Draves
No Relationships to Disclose
 
Gordon Goolamier
No Relationships to Disclose
 
Samantha Rosey
No Relationships to Disclose
 
Adam Calaway
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)
 
Lee Evan Ponsky
Stock and Other Ownership Interests - Walden Medical
Patents, Royalties, Other Intellectual Property - Uretheral Stent Co.
(OPTIONAL) Uncompensated Relationships - PRiiMO
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Seagen
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)